TY  - JOUR
AU  - Larkin, James
AU  - Weber, Jeffrey
AU  - Del Vecchio, Michele
AU  - Gogas, Helen
AU  - Arance, Ana M
AU  - Dalle, Stephane
AU  - Cowey, C Lance
AU  - Schenker, Michael
AU  - Grob, Jean-Jacques
AU  - Chiarion-Sileni, Vanna
AU  - Márquez-Rodas, Iván
AU  - Butler, Marcus O
AU  - Di Giacomo, Anna Marie
AU  - Middleton, Mark R
AU  - De la Cruz-Merino, Luis
AU  - Arenberger, Petr
AU  - Atkinson, Victoria
AU  - Hill, Andrew
AU  - Fecher, Leslie A
AU  - Millward, Michael
AU  - Khushalani, Nikhil I
AU  - Queirolo, Paola
AU  - Long, Georgina V
AU  - Lobo, Maurice
AU  - Askelson, Margarita
AU  - Ascierto, Paolo A
AU  - Mandalá, Mario
PY  - 2022
DO  - 10.1016/j.ejca.2022.06.041
UR  - http://hdl.handle.net/10668/22177
T2  - European journal of cancer (Oxford, England : 1990)
AB  - Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging...
LA  - en
KW  - AJCC-8 criteria
KW  - Distant metastases
KW  - Ipilimumab
KW  - Melanoma adjuvant therapy
KW  - Nivolumab
KW  - Recurrence-free survival
KW  - Stage 3
KW  - Adjuvants, Immunologic
KW  - Humans
KW  - Ipilimumab
KW  - Melanoma
KW  - Neoplasm Staging
KW  - Nivolumab
KW  - Skin Neoplasms
TI  - Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
TY  - research article
VL  - 173
ER  -